MedTrace Logo

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

NCT02343224 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-01-24

Study results available
· View outcomes & findings →

Summary

This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to treat brain tumors in a pediatric population. Researchers want to see if treatment with PEG-Intron will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic pathway gliomas.

The purposes of this study are:

* To learn more about the response to pegylated interferon
* To learn more about the side effects of pegylated interferon
* To learn more about MRI images in patients with Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas.
* To learn more about quality of life in patients treated with pegylated interferon

Conditions

  • Juvenile Pilocytic Astrocytomas
  • Optic Pathway Gliomas

Interventions

DRUG

Pegylated interferon alpha-2b

PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week

Sponsors & Collaborators

  • CURE Childhood Cancer, Inc.

    collaborator OTHER

  • Emory University

    lead OTHER

Principal Investigators

  • Dolly Aguilera, MD · Children's Healthcare of Atlanta/Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2020-11-11
Completion
2020-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02343224 on ClinicalTrials.gov